Key points are not available for this paper at this time.
Design
Review
Supports combined cardiorenal risk assessment in hypertension; leaves open dedicated trials of dual-protective therapies.
The kidney facilitates the development of arterial hypertension and suffers its consequences. Once renal damage is clinically manifested, a clear increase in cardiovascular risk appears. The coincidence of renal and cardiovascular damage strengthens the need for therapies attempting the simultaneous protection of both the kidney and the cardiovascular system.
No takes yet. Share an insight, caveat, or question.
Ruilope et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: